Please wait while the formulary information is being retrieved.
MOVANTIK (NALOXEGOL OXALATE)
- Opioid-induced constipation
12.5 mg tablet
- 1 tablet (12.5 mg) by oral route once daily in the morning
25 mg tablet
- 1 tablet (25 mg) by oral route once daily in the morning
Opioid-induced constipation
- 1 tablet (25 mg) by oral route once daily in the morning
- 2 tablets (25 mg) by oral route once daily in the morning
- 1 tablet (12.5 mg) by oral route once daily in the morning
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Gastrointestinal perforation
- Opioid withdrawal symptoms
Severe
Moderate
- None
MOVANTIK (NALOXEGOL OXALATE)
- Opioid-induced constipation
- None
- Acute abdominal pain
- Diarrhea
- Flatulence
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Hyperhidrosis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Gastrointestinal perforation
- Opioid withdrawal symptoms
- Urticaria
Less Severe
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Naloxegol
No safety and efficacy established in pediatrics.
- 1 Day – 18 Years
- No safety and efficacy established in pediatrics.
Naloxegol
- Severity Level:
2
- Additional Notes: May precipitate withdrawal symptoms in fetus and opioid dependent mother
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Naloxegol
Insufficient data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Opioid-induced constipation | |
K59.09 | Other constipation |
0-9 | A-Z |
---|---|
K59.09 | Other constipation |
Formulary Reference Tool